What should you know about stage 2 triple positive breast cancer?

Triple positive means the tumour tests positive for oestrogen receptors, progesterone receptors and HER2. These markers help clinicians choose medicines that block hormone signals or HER2 signalling. Stage 2 describes a tumour that is larger or involves nearby lymph nodes but has not been identified as distant spread in the staging assessment. The stage and receptor results answer different questions, so both appear in the diagnosis.

The pathology report may also describe grade, lymph-node findings and other features. A breast biopsy establishes the tissue diagnosis; imaging can show the breast and regional anatomy.

Your breast team may combine surgery, medicines given before or after surgery, radiotherapy and hormone-blocking treatment. The sequence depends on tumour size, lymph-node findings, menopausal status, heart health and your preferences. A sentinel lymph node biopsy may help assess the first draining nodes. Mammogram or breast MRI can contribute to planning, while gene-expression testing or genomic tumour profiling may be appropriate in selected cases. You can read about [Breast Biopsy], [Breast MRI], [Mammogram], [Sentinel Lymph Node Biopsy], [Breast Cancer Gene Expression Test] and [Genomic Tumour Profiling].

Tell your oncology team quickly about fever, new breathlessness, chest pain, severe diarrhoea, sudden swelling, a new neurological change or an allergic reaction during treatment. Report a new breast or underarm lump, wound drainage, increasing redness, uncontrolled pain or arm swelling so it can be assessed early.

Ask which receptor results were measured, whether lymph nodes are involved, whether treatment starts before surgery, and how each medicine will be monitored. Ask about fertility, heart monitoring, hormone treatment, surgery choices and the symptoms that warrant a same-day call.